Intractable XXXX : etiology, risk factors and treatment.

@entity1 @entity1032 @entity410 @entity75 @entity9357 @entity2916 @entity1315 @entity302 @entity14957
The data emerging from our study are the following: the presence of an identifiable cause is important: complications like @entity2916 or signs of marked @entity75 represent an adverse risk factor for IE. The presence of @entity302 among relatives, evidence of pre- or perinatal @entity75 , @entity1032 , and early onset, long periods of uncontrolled @entity410 before starting an adequate therapy and frequency of @entity410 appear to be indicative of an adverse prognosis, since differences between the two groups of responsive or unresponsive @entity1 are statistically significant. On the contrary, the occurrence of febrile @entity410 in the past history does not seem to have an adverse prognosis. @entity1315 and IS bear the worst prognosis. ME, CPS, GTCS, @entity14957 , @entity9357 and PM have a progressively better outcome in responsiveness to AEDs. Concerning therapy in @entity1 with IE, studies indicate the results of high dose monotherapy appear to be equal or better than with polypharmacy. Because of the gravity of the situation, trials with unconventional drugs have been performed, but it is too early to draw definite conclusions about the long-term usefulness of most of them. In conclusion, our data indicate that the appearance of an IE can be predicted utilizing the above mentioned criteria, considered either alone or in combination. The issue of IE remains undoubtedly an important one among the group of @entity410 . Further studies considering a greater number of @entity1 and new therpeutic strategies are to be recommended.
